FI820998L - 9-/2-(3-indolyl)etyl/-1-oxa-4,9-diazaspiro/5,5/undekan-3-oner - Google Patents

9-/2-(3-indolyl)etyl/-1-oxa-4,9-diazaspiro/5,5/undekan-3-oner

Info

Publication number
FI820998L
FI820998L FI820998A FI820998A FI820998L FI 820998 L FI820998 L FI 820998L FI 820998 A FI820998 A FI 820998A FI 820998 A FI820998 A FI 820998A FI 820998 L FI820998 L FI 820998L
Authority
FI
Finland
Prior art keywords
carbon atoms
etyl
oner
undecan
diazaspiro
Prior art date
Application number
FI820998A
Other languages
English (en)
Finnish (fi)
Inventor
Robin D Clark
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of FI820998L publication Critical patent/FI820998L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
FI820998A 1981-03-23 1982-03-22 9-/2-(3-indolyl)etyl/-1-oxa-4,9-diazaspiro/5,5/undekan-3-oner FI820998L (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/246,459 US4332804A (en) 1981-03-23 1981-03-23 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones

Publications (1)

Publication Number Publication Date
FI820998L true FI820998L (fi) 1982-09-24

Family

ID=22930776

Family Applications (1)

Application Number Title Priority Date Filing Date
FI820998A FI820998L (fi) 1981-03-23 1982-03-22 9-/2-(3-indolyl)etyl/-1-oxa-4,9-diazaspiro/5,5/undekan-3-oner

Country Status (19)

Country Link
US (1) US4332804A (da)
EP (1) EP0061333B1 (da)
JP (1) JPS57169485A (da)
KR (1) KR830009094A (da)
AT (1) ATE17249T1 (da)
AU (1) AU557094B2 (da)
BR (1) BR8201589A (da)
DE (1) DE3268225D1 (da)
DK (1) DK129282A (da)
ES (1) ES510649A0 (da)
FI (1) FI820998L (da)
IE (1) IE52652B1 (da)
IL (1) IL65310A (da)
NO (1) NO820937L (da)
NZ (1) NZ200085A (da)
PH (1) PH17233A (da)
PL (1) PL235561A1 (da)
PT (1) PT74626B (da)
ZA (1) ZA821929B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977178A (en) * 1982-09-20 1990-12-11 Pfizer Inc. Method of treating anxiety and depression with 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents
US4861880A (en) * 1982-09-20 1989-08-29 Pfizer Inc. 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents
US4879391A (en) * 1982-09-20 1989-11-07 Pfizer Inc. 1-Phenyl-2(1H,3H)-indolone psychotherapeutic agents
GB8808433D0 (en) * 1988-04-11 1988-05-11 Merck Sharp & Dohme Therapeutic agents
ATE348808T1 (de) 2000-03-06 2007-01-15 Acadia Pharm Inc Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
EP1461339B1 (en) * 2001-12-28 2010-04-28 Acadia Pharmaceuticals Inc. Spiroazacyclic compounds as monoamine receptor modulators
US7538222B2 (en) * 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7253186B2 (en) * 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
CA2490397A1 (en) * 2002-06-24 2003-12-31 Acadia Pharmaceuticals Inc. N-substituted piperidine derivatives as serotonin receptor agents
CN1816524B (zh) 2003-01-16 2012-06-27 阿卡蒂亚药品公司 用于神经退行性疾病的治疗的选择性五羟色胺2a/2c受体反向激动剂
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) * 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US7790899B2 (en) * 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
EP2289879B1 (en) * 2004-09-27 2014-11-12 Acadia Pharmaceuticals Inc. Synthesis of a crystalline form of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide tartrate salt
CA2681506C (en) 2007-03-19 2016-05-24 Perry Peters Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
HUE037639T2 (hu) * 2007-09-21 2018-09-28 Acadia Pharm Inc Pimavanszerin együttes beadása más szerekkel
TWI685497B (zh) * 2014-06-02 2020-02-21 西班牙商伊史帝夫製藥公司 具有多重模式抗疼痛活性的１-氧雜-４,９-二氮雜螺十一烷化合物之烷基衍生物
PT3325444T (pt) 2015-07-20 2021-09-22 Acadia Pharm Inc Métodos para preparar n-(4-fluorobenzil)-n-(1-metilpiperidina-4-il)-n'-(4-(2-metilpropiloxi)fenilmetil)carbamida e o seu sal de tartarato e forma polimórfica c
MX2018005439A (es) 2015-11-16 2018-11-09 Esteve Labor Dr Compuestos oxadiazoespiricos para el tratamiento del abuso y la adiccion a las drogas.
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
EP3558311A1 (en) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
EP3615028A1 (en) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
US20210077479A1 (en) 2017-08-30 2021-03-18 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
BR112020007359A2 (pt) 2017-10-17 2020-09-29 Esteve Pharmaceuticals, S.A. sais de (r)-9-(2,5-difluorofenetil)-4-etil-2-metil-1-oxa-4,9-diazaespiro[5.5]undecan-3-ona

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481942A (en) * 1968-09-06 1969-12-02 Smithkline Corp Oxa-diazaspiro(4.5)decane compounds
US3574204A (en) * 1969-07-03 1971-04-06 Yoshitomi Pharmaceutical Piperidine spiro compounds
CA952908A (en) * 1970-02-27 1974-08-13 Yoshitomi Pharmaceutical Industries Benzodioxane derivatives
US3723442A (en) * 1970-12-31 1973-03-27 Yoshitomi Pharmaceutical 3-oxo-1-oxa-4,8-diazaspiro(4.5)decanes
US4255432A (en) * 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof

Also Published As

Publication number Publication date
DE3268225D1 (de) 1986-02-13
EP0061333A1 (en) 1982-09-29
ES8306373A1 (es) 1983-06-01
IL65310A (en) 1985-03-31
ES510649A0 (es) 1983-06-01
US4332804A (en) 1982-06-01
NO820937L (no) 1982-09-24
AU557094B2 (en) 1986-12-04
ZA821929B (en) 1983-11-30
AU8176982A (en) 1982-09-30
PH17233A (en) 1984-07-03
DK129282A (da) 1982-09-24
NZ200085A (en) 1985-07-12
BR8201589A (pt) 1983-02-08
EP0061333B1 (en) 1986-01-02
ATE17249T1 (de) 1986-01-15
PL235561A1 (da) 1982-10-25
IL65310A0 (en) 1982-05-31
PT74626B (en) 1983-12-19
PT74626A (en) 1982-04-01
IE820648L (en) 1982-09-23
JPS57169485A (en) 1982-10-19
IE52652B1 (en) 1988-01-06
KR830009094A (ko) 1983-12-17

Similar Documents

Publication Publication Date Title
FI820998L (fi) 9-/2-(3-indolyl)etyl/-1-oxa-4,9-diazaspiro/5,5/undekan-3-oner
ES486349A1 (es) Procedimiento para la preparacion de 5-(2-imidazolin-2-il)- aminopirimidinas
DE3272476D1 (en) Process for the preparation of indole derivatives, their use as intermediates, and 4-hydroxy indoles
FI820295L (fi) Nya kefemkompositioner och foerfarande foer deras framstaellning
NZ213104A (en) Tryptamine derivatives and pharmaceutical compositions
IE820401L (en) N-£4-(indolyl)-piperidino-alkyl|-benzimidazolines
GR3004855T3 (da)
ATE29721T1 (de) 5-(4-vinyl- oder 4-ethynylbenzoyl)-1,2-dihydro-3h-pyrrolo-(1,2-a -pyrrol-1-carbosaeure und deren derivate.
GR79170B (da)
NO822828L (no) Analogifremgangsmaate ved fremstilling av terapeutisk virksomme 1-fenylindazol-3-on-forbindelser og deres salter
TW225989B (da)
SE8002545L (sv) Arylsubstituerade furaner och sett for framstellning derav
GR3006108T3 (da)
BE896098A (fr) Procede de modulation de la reponse immunitaire avec des dibenzocycloheptenylidenes
DE3271277D1 (en) Tropyl and pseudotropyl alkyl-benzoates and their use in migraine treatment

Legal Events

Date Code Title Description
FD Application lapsed

Owner name: SYNTEX (USA) INC